Drug Trial Radar · NCT07284654
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,049
Actual
Start
Dec 1, 2025
Primary completion
Sep 17, 2026
Study completion Sep 17, 2026
Sponsor
- Lead sponsor
- Vaxcyte, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.
Conditions
- Pneumococcal Disease
Interventions
31 valent pneumococcal conjugate vaccineBiological
0.5 mL of VAX-31 will be administered into the deltoid muscle
PCV20Biological
0.5 mL of the 20 valent pneumococcal conjugate vaccine will be administered into the deltoid muscle
PCV21Biological
0.5 mL of the 21 valent pneumococcal conjugate vaccine will be administered into the deltoid muscle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and aboveTime frame: 1 month after vaccination
- Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site)Time frame: up to 7 days after vaccination
- Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain)Time frame: up to 7 days after vaccination
- Percentage of subjects reporting unsolicited AETime frame: up to 31 days after vaccination
- Percentage of subjects reporting serious adverse events (SAE), new onset of chronic illness (NOCI), and medically attended adverse events (MAAE)Time frame: up to 6 Months after vaccination
- Serotype-specific OPA geometric mean titers (GMT) in 18 to 49 year olds and 50 to 64 year oldsTime frame: 1 month after vaccination
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Accel Research Site - Achieve - Birmingham - ERN
Birmingham, Alabama
Center for Indigenous Health - Chinle - Johns Hopkins Project
Chinle, Arizona
Center for Indigineous Health - Whiteriver - John Hopkins Project
Whiteriver, Arizona
Clinical Innovations Trials - Riverside - CenExel
Riverside, California
Research Centers of America - Hollywood - CenExel
Hollywood, Florida
Health Awareness - Jupiter - ERN
Jupiter, Florida
Suncoast Research Group LLC
Miami, Florida
Precision Clinical Research - Sunrise
Sunrise, Florida
Clinical Research Atlanta - Headlands
Stockbridge, Georgia
Velocity Clinical Research - Valparaiso (Buynak Clinical Research)
Valparaiso, Indiana
Johnson County Clin-Trials - JCCT
Lenexa, Kansas
Alliance for Multispecialty Research, LLC - West Wichita
Wichita, Kansas
DelRicht Clinical Research, LLC - New Orleans
New Orleans, Louisiana
Headlands Research - Detroit - Headlands
Southfield, Michigan
DelRicht Research, LLC - Gulfport
Gulfport, Mississippi
Sky Integrative Medical Center - SKYCRNG
Ridgeland, Mississippi
Alliance for Multispecialty Research, LLC - Kansas City
Kansas City, Missouri
Velocity Clinical Research
Omaha, Nebraska
Advanced Memory Research Institute - CenExe
Toms River, New Jersey
Center for Indigineous Health - Gallup - John Hopkins Project
Gallup, New Mexico
Center for Indigineous Health - Shiprock - John Hopkins Project
Shiprock, New Mexico
Rochester Clinical Research - ATLAS - Rochester
Rochester, New York
CTI Clinical Research Center
Cincinnati, Ohio
Lynn Institute of Norman
Norman, Oklahoma
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania
Coastal Carolina Research Center - Alcanza - HyperCore
North Charleston, South Carolina
Flourish Research - San Antonio
San Antonio, Texas
DM Clinical Research - Sugarland
Sugar Land, Texas
JBR Clinical Research - CenExel JBR
Salt Lake City, Utah
Charlottesville Medical Research Center - Alcanza - HyperCore
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.